**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 90049

**Manuscript Type:** SYSTEMATIC REVIEWS

**Quality of life after pancreatic surgery**

Li SZ *et al*. QOL after pancreatic surgery

Shi-Zhen Li, Ting-Ting Zhen, Yi Wu, Min Wang, Ting-Ting Qin, Hang Zhang, Ren-Yi Qin

**Shi-Zhen Li, Ting-Ting Zhen, Yi Wu, Min Wang, Ting-Ting Qin, Hang Zhang, Ren-Yi Qin,** Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

**Co-corresponding authors:** Hang Zhang and Ren-Yi Qin.

**Author contributions:** Li SZ, Zhang H, and Qin RY designed the research; Wu Y and Qin TT analyzed the data; Li SZ and Zhen TT wrote original draft; Wang M and Zhang H reviewed and edited the draft; All authors have read and approve the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 82273442 and No. 82273438.

**Corresponding author: Ren-Yi Qin, FACS, PhD, Chief Doctor,** Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. ryqin@tjh.tjmu.edu.cn

**Received:** December 1, 2023

**Revised:** December 29, 2023

**Accepted:** January 31, 2024

**Published online:**

**Abstract**

BACKGROUND

Pancreatic surgery is challenging owing to the anatomical characteristics of the pancreas. Increasing attention has been paid to changes in quality of life (QOL) after pancreatic surgery.

AIM

To summarize and analyze current research results on QOL after pancreatic surgery.

METHODS

A systematic search of the literature available on PubMed and EMBASE was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were identified by screening the references of retrieved articles. Studies on patients’ QOL after pancreatic surgery published after January 1, 2012, were included. These included prospective and retrospective studies on patients' QOL after several types of pancreatic surgeries. The results of these primary studies were summarized inductively.

RESULTS

A total of 45 articles were included in the study, of which 13 were related to pancreaticoduodenectomy (PD), seven to duodenum-preserving pancreatic head resection (DPPHR), nine to distal pancreatectomy (DP), two to central pancreatectomy (CP), and 14 to total pancreatectomy (TP). Some studies showed that 3-6 months were needed for QOL recovery after PD, whereas others showed that 6-12 months was more accurate. Although TP and PD had similar influences on QOL, patients needed longer to recover to preoperative or baseline levels after TP. The QOL was better after DPPHR than PD. However, the superiority of the QOL between patients who underwent CP and PD remains controversial. The decrease in exocrine and endocrine functions postoperatively was the main factor affecting the QOL. Minimally invasive surgery could improve patients’ QOL in the early stages after PD and DP; however, the long-term effect remains unclear.

CONCLUSION

The procedure among PD, DP, CP, and TP with a superior postoperative QOL is controversial. The long-term benefits of minimally invasive versus open surgeries remain unclear. Further prospective trials are warranted.

**Key Words:** Quality of life; Pancreaticoduodenectomy; Duodenum-preserving pancreatic head resection; Distal pancreatectomy; Central pancreatectomy; Total pancreatectomy

Li SZ, Zhen TT, Wu Y, Wang M, Qin TT, Zhang H, Qin RY. Quality of life after pancreatic surgery. *World J Gastroenterol* 2024; In press

**Core Tip:** This review summarizes and analyzes current research results on quality of life (QOL) after pancreatic surgery. The article covers the discussion and analysis of the QOL of various pancreatic surgeries. Which kind of surgical procedure has better QOL is controversial. The long-term benefits on QOL of minimally invasive surgery over open surgery are controversial.

**INTRODUCTION**

The pancreas, located in the retroperitoneum, is a glandular organ with endocrine and exocrine functions. It can be divided into four main parts: Head, neck, body, and tail. Pancreatic surgery can be divided into pancreaticoduodenectomy (PD), duodenum-preserving pancreatic head resection (DPPHR), distal pancreatectomy (DP), central pancreatectomy (CP), and total pancreatectomy (TP). Pancreatic surgery is challenging due to the organ’s complex anatomical structure, peripheral vascularity, and intractable postoperative complications. Following the standardization of surgical steps and improvements in relevant medical techniques and surgical instruments, the safety of pancreatic surgery has significantly improved. Perioperative morbidity, mortality, and other related indicators have become more acceptable. However, owing to the organ’s essential role in digestion, absorption, and blood glucose regulation, changes in the quality of life (QOL) of patients after pancreatic surgery have attracted the attention of surgeons.

More patients with non-malignant pancreatic diseases are willing to undergo surgical treatment because of the acceptable safety. In this case, from the perspective of the patient postoperatively, the significance of rehabilitation reflects the traditional perioperative outcome and QOL[1]. The QOL is a new concept that extends beyond health. Although there is no consensus on its conception[2], we can consider it a multi-dimensional architecture that incorporates objective and individual subjective views of aspects of one’s physical, psychological, and social well-being[3-5]. It includes evaluating physical health, and many subscales, such as emotion, job, culture, family, sociability, economy, cognition, happiness, sex, and some symptoms[6]. Since people have realized the importance of QOL, many QOL scales have emerged, including the European Organization for Research and Treatment of Cancer QLQ-C30, European Quality of Life 5-dimension, 36-item Short, *etc.* However, it is challenging to follow up on patients’ QOL once they are discharged from the hospital. Consequently, most relevant studies had small sample sizes or lacked long-term follow-up results. Moreover, a summary of studies on QOL after pancreatic surgery is lacking.

This study assessed the QOL in patients who underwent PD, DPPHR, DP, CP and TP. We conducted this study to describe the existing findings on the QOL after pancreatic surgery to make it easier for surgeons and patients to decide on a surgical approach. In addition, we attempted to identify controversial results to encourage further targeted research.

**MATERIALS AND METHODS**

***Search strategy***

This systematic review was conducted using PubMed and EMBASE databases, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline[7]. Two authors (Li and Zhen) independently screened the articles after removing duplicates. Our search algorithm combined the terms: (1) “Pancreatic surgery” OR “pancreatoduodenectomy” OR “duodenum-preserving pancreatic head resection” OR “distal pancreatectomy” OR “central pancreatectomy” OR “total pancreatectomy”; and (2) “Quality of life”. Only articles written in English were included. The references of retrieved articles were screened for any relevant articles.

***Inclusion and exclusion criteria***

Inclusion criteria: Articles involving the QOL of patients who underwent PD, DPPHR, DP, CP, and TP were included. The exclusion criteria were as follows: (1) Articles not within the scope of interest of this review; (2) Overlapping patient data; (3) Articles not published in English; and (4) Articles published before January 1, 2012.

**RESULTS**

***Literature search***

The search results are shown in Figure 1. A total of 1515 potential studies were identified: 1313 from PubMed, 190 from EMABASE, and 12 additional references through a manual search. After excluding duplicates, 1453 articles were left. However, after screening titles and abstracts, 872 articles were excluded because they were outside the scope of this review. We also excluded article that were inaccessible (*n* = 127). A total of 454 full-text articles were collected, of which 312 were excluded for language (*n* = 11), not addressing the QOL after PD, DPPHR, DP, CP, or TP (*n* = 301), or being published before January 1, 2012 (*n* = 97). After the selection process, 45 clinical studies were included. The 45 articles included13 on PD, seven on DPPHR, nine on DP, two on CP, and 14 on TP.

***Study characteristics for PD***

Thirteen studies, including three randomized controlled trials (RCTs), four prospective observational studies, and six retrospective studies on PD were assessed. Six studies focused on perioperative QOL in patients with PD. Two RCTs and one retrospective study reported postoperative QOL changes after two years (Table 1). Some studies demonstrated that patients’ QOL significantly diminished within one month post-operatively and nearly recovered to preoperative or baseline levels at three months after PD regardless of the pathology type[8-11], others reported that six months even one year was a more accurate period[12-14]. For long-term survivors, gastrointestinal symptoms such as bloating and indigestion are factors that affect their long-term QOL, and some of these symptoms are caused by pancreatic exocrine insufficiency after PD instead of post-operative complications[15,16]. Studies have reported that nearly half of the survivors required pancrelipase after PD[9,17,18]. Pancrelipase can improve nutritional status; however, its capacity to improve QOL is controversial[9,13,19].

Most studies have demonstrated that no differences between pylorus-preserving PD (PPPD) and conventional PD overall mortality, morbidity, survival, and QOL[20-24]. Studies have also shown that preoperative body weight loss, impaired preoperative pancreatic exocrine function, longer operative time, intraoperative radiotherapy, pancreatic carcinoma, and postoperative diarrhea may result in delayed QOL recovery[25].

Laparoscopic PD (LPD) could provide better QOL for patients with better functional status within six months postoperatively[26]. However, this advantage disappears after six months[27].

***Study characteristics for DPPHR***

Table 2 summarizes the results of the included articles on DPPHR. The sample sizes of the seven studies were 74, 80, 25, 40, 85, 17, and 16. Only one study examined the change in QOL within one year. One group of researchers reported that DPPHR and PD were comparatively effective in improving long-term QOL postoperatively[28-30]. Another group held that DPPHR could bring about better outcomes in the form of less frequent nausea, pain, and diarrhea, better physical status, working ability, and global QOL[31].

Studies have found that the Frey and the Berne approach had the advantages of shorter operation time and hospital stay duration compared to the Beger’s. However, none showed any obvious difference in improving the patients’ postoperative QOL[32-35].

***Study characteristics for DP***

Nine studies included patients who underwent DP (Table 3). Two studies reported the perioperative QOL of patients who underwent DP, and seven mainly compared the differences between open and minimally invasive methods. Studies have shown that minimally invasive DP (MIDP) results in shorter hospital stays and functional recovery time compared to open DP (ODP)[36,37]. The MIDP group had better short-term QOL than the ODP group for up to 30 d postoperatively[38,39]. However, which is better for long-term QOL of > 1 year is controversial. During this period, some studies demonstrated no difference between MIDP and ODP[38,40], while others reported that MIDP could bring about better QOL for patients regarding physical, cognitive, social, and role functions, and symptoms, such as nausea, vomiting, and insomnia[41,42].

Laparoscopic spleen-preserving DP (LSPDP) and laparoscopic DP with splenectomy (LDPS) had similar perioperative outcomes[43]. Patients who underwent LSPDP had significantly better vitality than those who underwent LDPS, and were less likely to contract the common cold and flu[44,45].

The modified Appleby improved the ratio of R0 resection, relieved pain and improved patients’ overall QOL[46].

***Study characteristics for CP***

Details of the two studies on CP with sample sizes of 36 and 42 are included in Table 3. Laparoscopic CP can help patients maintain better working and living conditions than open CP[47]. While comparing DP and PD, some researchers thought that CP showed a significant benefit in specific symptoms, such as loss of appetite, insomnia, nausea, and vomiting[48]. Others held different opinions that CP was associated with better pancreatic function but the same or even worse long-term QOL and significantly increased post-operative morbidity and risk than DP or PD[49,50].

***Study characteristics for TP***

The two studies on TP were prospective observational studies (Table 4). Two articles showed the results of QOL within one year. It has been extensively verified that the perioperative and long-term outcomes of TP are comparable to those of PD regarding morbidity, mortality, survival rates, and QOL, regardless of patient age or tumor pathology[51-55]. One study demonstrated that the long-term post-operative QOL of patients who underwent TP was lower than that of the general population[56], however, more studies reported no significant differences[57,58]. Regarding pain relief, especially for most patients with narcotic-dependent, TP could alleviate pain largely such that half of the patients with chronic pancreatitis patients could be relieve from narcotics and return to normal life a year after surgery. However, it is a continuous improvement process. Over time, an increasing number of patients no longer required narcotics to control their abdominal pain[59-63]. More than half of the patients reported that their bowel habits had changed; therefore, they needed to take pancreatin[64-66]. A quarter to more than half of the patients, especially children, achieved insulin independence after islet cell autotransplantation (IAT)[67]. Although the insulin independence rate could decline over time, most patients could almost control their glycemic stability with an acceptable dose of insulin[60,61,68-70]. The stable control of glucose provides a more enjoyable life with better QOL for patients to have a normal social, work and study life[71].

**DISCUSSION**

***PD***

PD, developed by Kausch[72] and Whipple *et al*[73], is a major surgical procedure used to treat middle and lower-segment cancers of the common bile duct and the periampullary region. The safety of PD has improved significantly in recent years. The mortality rate of PD has decreased from > 50% to < 5%, and the incidence of surgical complications has also decreased significantly[74]. Under these circumstances, attention gradually shifted from safe hospital discharge to the recovery of QOL. Therefore, an increasing number of studies have assessed the changes in patients’ QOL after PD. However, these studies came from different countries with different demographic characteristics and almost always had small sample sizes, especially prospective studies. As shown in Table 1, seven of the studies had a sample size of < 100 participants, and only one had a sample size of more than 300.

PPPD was first performed in 1944 by Watson[75] and was popularized by Traverso and Longmire[76]. Although the merits of PPPD versus classic PD are still debated, especially regarding perioperative risk, PPPD provides surgeons with another option[77]. Most studies have demonstrated that PPPD and PD have similar effects on patients’ QOL. Factors leading to the delayed recovery of QOL, such as preoperative body weight loss and impaired preoperative pancreatic exocrine function, are currently being explored.

Traditionally, PD was performed openly. Since the first case described by Gagner and Pomp[78] in 1994, many surgeons have explored the advantages of LPD and open PD (OPD). Our previous multi-center, open-label, RCT proved that LPD was associated with a shorter length of stay, similar short-term morbidity, and mortality rates as OPD. Due to the better safety of LPD and the maturity of surgical techniques, an increasing number of surgeons are focusing on comparing the differences in QOL between LPD and OPD. LPD have a better QOL advantage than OPD in the first six months, however, our new study showed that this advantage disappears three years postoperatively[27]. However, owing to the difficulty in collecting data, most related research data are unrepresentative. Therefore, high-quality RCTs should be performed in the future.

***DPPHR***

PD was surgeons’ first choice for benign or low-grade malignant lesions of the pancreatic head until the emergence of DPPHR. For these patients, since Beger *et al*[79] developed DPPHR in the early 1970s, another choice has emerged; with DPPHR, more organs are preserved, which could result in better endocrine and exocrine function postoperatively. Therefore, many studies have focused on prioritizing PD and DPPHR. Except for the perioperative parameters, whether DPPHR is superior to PD regarding QOL is still controversial[80]. Most researchers believe that DPPHR and PD relieve obstruction of the pancreatic head, which was the cause of the symptoms. Therefore, they have no significant influence on long-term QOL postoperatively[28,29]. Another study also suggested that increased digestive tract reconstruction during PD surgery lead to lower exocrine function and worse QOL postoperatively[31]. However, this study had poor representativeness because of its smaller sample size and earlier publication time.

Modifications of the original Beger procedure appeared, such as those by Frey and Berne, as people realized its superiority[81,82]. Compared to the Beger, Frey and Berne were technically more straightforward. All patients maintained the same pancreatic volume and exocrine and endocrine functions. Therefore, they had advantages regarding operation time and duration of hospital stay but showed no noticeable difference in improving postoperative QOL[32-35]. In conclusion, surgeons can choose any of them based on their expertise and intraoperative findings. Owing to the shorter operation time and length of hospital stay, modifications to the original Beger procedure should be preferred.

***DP***

DP is the standard surgical method for treating tumors of the pancreatic body or tail. Traditionally, it has been performed using an open approach. However, due to technological developments in laparoscopic and robotic instruments, MIDP is routinely performed by surgeons worldwide. Nearly all studies have demonstrated that MIDP can result in better QOL than ODP perioperatively. However, which is better in the long-term remains controversial. Larger sample sizes and more convincing studies have reported no long-term differences between MIDP and ODP[38,40].

While performing DP, the traditional approach is to remove the spleen because it is closely attached to the distal pancreas anatomically. As people realize the function of the spleen, an increasing number of surgeons are choosing to perform LSPDP for benign and low-malignancy tumors of the distal pancreas. Due to the preservation of the spleen in LSPDP, it is clear that LSPDP is superior to LDPS regarding QOL[44,45].

Appleby surgery was first performed in 1976 for the treatment of progressive carcinoma[83] of pancreatic body and tail. Owing to the difficulty of Appleby technology and the advent of neoadjuvant therapy, the number of Appleby surgeries is decreasing; therefore, there is a lack of relevant studies concerning QOL after Appleby.

***CP***

Guillemin successfully performed CP by anastomosis to both pancreatic remnants with an omega-shaped jejunal loop in 1957[84]. Letton and Wilson[85] completed the procedure in two patients with pancreatic injury with a Roux-en-Y jejunal loop anastomosis to the tail and closure to the head remnant[85]. An increasing number of surgeons prefer to perform this procedure in cases where the lesion is limited to the pancreatic neck or body. A normal pancreas has significantly less parenchymal loss, which means that more pancreatic function can be retained. According to previous studies, functional recovery and mean QOL are comparable to those of a standard control population[48]. It is generally believed that patients who underwent CP have a better QOL, but a higher perioperative risk[47-50]. However, studies on the QOL after CP are lacking.

***TP***

Since Rockey[86] performed the first TP in a patient with pancreatic cancer in 1943, some surgeons have attempted to perform the same procedure. However, owing to poor perioperative outcomes and QOL in the beginning, the feasibility of TP has been questioned. Many studies have been conducted to answer this question. The safety of TP has improved dramatically owing to mature surgical techniques and other factors. Impaired exocrine function is also one of the reasons why the feasibility of TP has been questioned. However, the optimization of pancreatin improved the patients’ exocrine function. Another reason is the high risk of brittle diabetes. Many factors are associated with insulin independence, such as non-hereditary chronic pancreatitis, younger age, lower body surface area, and higher total islet equivalents. The pancreas is the only organ that produces insulin. Due to the removal of the entire pancreas, TP causes great damage to patients’ ability to maintain stable blood sugar levels. To solve this problem, a new technology, the IAT, was first described in 1977. In IAT, islet cells are isolated from patients and transplanted into the portal vein. With the advent of pancreatin and IAT, the endocrine and exocrine functions of patients after TP have significantly improved[64-66]. It seems unlikely that TP can maintain or improve patients’ QOL. However, this was only possible if the patient had preoperative endocrine and exocrine pancreatic dysfunction or chronic pain. TP improved the QOL of these patients to some extent. In conclusion, TP can be considered in selected patients with neoplasms involving the entire pancreas or refractory chronic pancreatitis, regardless of the age of patients and pathology of the neoplasms.

**CONCLUSION**

Due to the importance of the endocrine and exocrine functions of the pancreas, surgeons have attempted to preserve normal pancreatic tissue and surrounding organs. Therefore, different surgical procedures have been developed depending on the location of the neoplasms. However, regardless of the procedure type, perioperative outcomes were generally acceptable. PD and TP had similar effects on patients’ QOL. The time that patients needed to recover to the preoperative or baseline level was 3-6 months after PD, but longer after TP. At this stage, more than half of the patients still required pancreatin to relieve gastrointestinal symptoms. Most studies have demonstrated that PPPD has a similar influence on perioperative and long-term outcomes as PD. DPPHR could provide better QOL with less pain, nausea, and diarrhea symptoms, and better physical and working status. In addition, owing to the higher incidence of perioperative complications in CP than in PD, whether CP could provide a better QOL remains debatable. As far as minimally invasive surgery is concerned, it seems that they could indeed produce better QOL in the early stages after PD and DP, but the long-term outcomes still need to be confirmed by more studies. In DP, preservation of the spleen can preserve the immunological function of the patients to defeat the usual virus.

This study has some shortcomings. We did not complete a systematic analysis of the data from previous studies, but only analyzed their conclusions. The scope of our study was not comprehensive enough, and some surgical procedures were not included. However, our goal was to provide directions for future research.

It is so big a project to collect data about patients’ postoperative QOL levels that the majority of studies do not have enough cases. It is not easy to contact patients via e-mail or phone once they are discharged from hospital. This means that incomplete data are common, especially when collecting long-term outcomes. As shown in the table, the rate of loss to follow-up was high, and there was a lack of prospective studies, especially randomized controlled studies. We propose conducting well-designed prospective analyses to verify our results.

**ARTICLE HIGHLIGHTS**

***Research background***

Pancreatic surgery is challenging because of the anatomical characteristics of pancreas. With the progress of medical standards, the perioperative outcomes have been greatly improved these years. More and more attention has been paid to the changes of quality of life (QOL) after pancreatic surgery. There is a lack of summary of QOL after various kinds of pancreatic surgery. With the purpose of describing the results of existing researches concerning QOL of pancreatic surgery we conducted this study.

***Research motivation***

Understanding which kind of pancreatic surgery has better QOL can provide some basis for clinical surgical decision.

***Research objectives***

This review aimed to summarize and analyze current research results on QOL after pancreatic surgery including pancreaticoduodenectomy, duodenum-preserving pancreatic head resection, distal pancreatectomy, central pancreatectomy and total pancreatectomy after January 1, 2012. It provides some directions for future researches based on the results of the controversy over patients' QOL after surgery. And it also provides some basis for clinical surgical decision-making.

***Research methods***

A systematic review was conducted in PubMed and EMBASE Database, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. And references of the retrieved articles were screened for any relevant articles. We extracted the results of these articles and summarized them.

***Research results***

This review summarizes and analyzes current research results on QOL after pancreatic surgery. The article covers the discussion and analysis of the QOL of various pancreatic surgery. Which kind of surgical procedure has better QOL is controversial. The long-term benefits on QOL of minimally invasive surgery over open surgery are controversial.

***Research conclusions***

Comparison and summary of QOL in patients with different types of pancreatic surgery. We included not only the results of the same surgical procedure, but also the results between different procedures.

***Research perspectives***

More well-designed prospective analyses of patients' QOL after pancreatic surgery are needed.

**ACKNOWLEDGEMENTS**

We appreciate the efforts of all surgeons at the centers where the included articles originated. We are grateful to the patients who participated in this trial. We thank the editors and reviewers for their helpful feedback, which has improved this paper.

**REFERENCES**

1 **Rajabiyazdi F**, Alam R, Pal A, Montanez J, Law S, Pecorelli N, Watanabe Y, Chiavegato LD, Falconi M, Hirano S, Mayo NE, Lee L, Feldman LS, Fiore JF Jr. Understanding the Meaning of Recovery to Patients Undergoing Abdominal Surgery. *JAMA Surg* 2021; **156**: 758-765 [PMID: 33978692 DOI: 10.1001/jamasurg.2021.1557]

2 **Moons P**, Budts W, De Geest S. Critique on the conceptualisation of quality of life: a review and evaluation of different conceptual approaches. *Int J Nurs Stud* 2006; **43**: 891-901 [PMID: 16696978 DOI: 10.1016/j.ijnurstu.2006.03.015]

3 **Panzini RG**, Mosqueiro BP, Zimpel RR, Bandeira DR, Rocha NS, Fleck MP. Quality-of-life and spirituality. *Int Rev Psychiatry* 2017; **29**: 263-282 [PMID: 28587554 DOI: 10.1080/09540261.2017.1285553]

4 **Carr AJ**, Gibson B, Robinson PG. Measuring quality of life: Is quality of life determined by expectations or experience? *BMJ* 2001; **322**: 1240-1243 [PMID: 11358783]

5 **Henry M**, Poyser T, Bampoe S. The surgical epidemic. *Br J Hosp Med (Lond)* 2017; **78**: 612-615 [PMID: 29111808 DOI: 10.12968/hmed.2017.78.11.612]

6 **Rubin RR**, Peyrot M. Quality of life and diabetes. *Diabetes Metab Res Rev* 1999; **15**: 205-218 [PMID: 10441043 DOI: 10.1002/(sici)1520-7560(199905/06)15:3<205::aid-dmrr29>3.0.co;2-o]

7 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

8 **Laitinen I**, Sand J, Peromaa P, Nordback I, Laukkarinen J. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy. *Pancreatology* 2017; **17**: 445-450 [PMID: 28274687 DOI: 10.1016/j.pan.2017.02.013]

9 **Fong ZV**, Alvino DM, Castillo CF, Nipp RD, Traeger LN, Ruddy M, Lubitz CC, Johnson CD, Chang DC, Warshaw AL, Lillemoe KD, Ferrone CR. Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. *Ann Surg* 2017; **266**: 685-692 [PMID: 28657944 DOI: 10.1097/SLA.0000000000002380]

10 **Nieveen van Dijkum EJ**, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ. Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. *Br J Surg* 2005; **92**: 471-477 [PMID: 15672431 DOI: 10.1002/bjs.4887]

11 **Gerstenhaber F**, Grossman J, Lubezky N, Itzkowitz E, Nachmany I, Sever R, Ben-Haim M, Nakache R, Klausner JM, Lahat G. Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life? *J Am Geriatr Soc* 2013; **61**: 1351-1357 [PMID: 23865843 DOI: 10.1111/jgs.12360]

12 **Chan C**, Franssen B, Domínguez I, Ramírez-Del Val A, Uscanga LF, Campuzano M. Impact on quality of life after pancreatoduodenectomy: a prospective study comparing preoperative and postoperative scores. *J Gastrointest Surg* 2012; **16**: 1341-1346 [PMID: 22547348 DOI: 10.1007/s11605-012-1898-2]

13 **Allen CJ**, Yakoub D, Macedo FI, Dosch AR, Brosch J, Dudeja V, Ayala R, Merchant NB. Long-term Quality of Life and Gastrointestinal Functional Outcomes After Pancreaticoduodenectomy. *Ann Surg* 2018; **268**: 657-664 [PMID: 30199443 DOI: 10.1097/SLA.0000000000002962]

14 **Rees JR**, Macefield RC, Blencowe NS, Alderson D, Finch-Jones MD, Blazeby JM. A prospective study of patient reported outcomes in pancreatic and peri-ampullary malignancy. *World J Surg* 2013; **37**: 2443-2453 [PMID: 23716026 DOI: 10.1007/s00268-013-2104-8]

15 **Heerkens HD**, van Berkel L, Tseng DSJ, Monninkhof EM, van Santvoort HC, Hagendoorn J, Borel Rinkes IHM, Lips IM, Intven M, Molenaar IQ. Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. *HPB (Oxford)* 2018; **20**: 188-195 [PMID: 29092792 DOI: 10.1016/j.hpb.2017.09.003]

16 **Balduzzi A**, Marchegiani G, Andrianello S, Romeo F, Amodio A, De Pretis N, Zamboni G, Malleo G, Frulloni L, Salvia R, Bassi C. Pancreaticoduodenectomy for paraduodenal pancreatitis is associated with a higher incidence of diabetes but a similar quality of life and pain control when compared to medical treatment. *Pancreatology* 2020; **20**: 193-198 [PMID: 31952917 DOI: 10.1016/j.pan.2019.12.014]

17 **Fong ZV**, Ferrone CR. ASO Author Reflections: Long-Term Impact of Pancreatoduodenectomy on Pancreas-Specific Quality of Life. *Ann Surg Oncol* 2021; **28**: 4225-4226 [PMID: 33759048 DOI: 10.1245/s10434-021-09859-2]

18 **Jung W**, Kim H, Kwon W, Jang JY. Atrophy of remnant pancreas after pancreatoduodenectomy: Risk factors and effects on quality of life, nutritional status, and pancreatic function. *J Hepatobiliary Pancreat Sci* 2022; **29**: 239-249 [PMID: 33773065 DOI: 10.1002/jhbp.949]

19 **Kim H**, Yoon YS, Han Y, Kwon W, Kim SW, Han HS, Yoon DS, Park JS, Park SJ, Han SS, Lee SE, Choi SH, Han IW, Kim E, Jang JY. Effects of Pancreatic Enzyme Replacement Therapy on Body Weight and Nutritional Assessments After Pancreatoduodenectomy in a Randomized Trial. *Clin Gastroenterol Hepatol* 2020; **18**: 926-934.e4 [PMID: 31520730 DOI: 10.1016/j.cgh.2019.08.061]

20 **Hüttner FJ**, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, Diener MK. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. *Cochrane Database Syst Rev* 2016; **2**: CD006053 [PMID: 26905229 DOI: 10.1002/14651858.CD006053.pub6]

21 **Diener MK**, Heukaufer C, Schwarzer G, Seiler CM, Antes G, Buchler M, Knaebel HP. Pancreaticoduodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. *Cochrane Database Syst Rev* 2008: CD006053 [PMID: 18425935 DOI: 10.1002/14651858.CD006053.pub2]

22 **Diener MK**, Knaebel HP, Heukaufer C, Antes G, Büchler MW, Seiler CM. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. *Ann Surg* 2007; **245**: 187-200 [PMID: 17245171 DOI: 10.1097/01.sla.0000242711.74502.a9]

23 **Seiler CA**, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Büchler MW. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. *Br J Surg* 2005; **92**: 547-556 [PMID: 15800958 DOI: 10.1002/bjs.4881]

24 **Klaiber U**, Probst P, Hüttner FJ, Bruckner T, Strobel O, Diener MK, Mihaljevic AL, Büchler MW, Hackert T. Randomized Trial of Pylorus-Preserving vs. Pylorus-Resecting Pancreatoduodenectomy: Long-Term Morbidity and Quality of Life. *J Gastrointest Surg* 2020; **24**: 341-352 [PMID: 30671796 DOI: 10.1007/s11605-018-04102-y]

25 **Ohtsuka T**, Yamaguchi K, Chijiiwa K, Kinukawa N, Tanaka M. Quality of life after pylorus-preserving pancreatoduodenectomy. *Am J Surg* 2001; **182**: 230-236 [PMID: 11587683 DOI: 10.1016/s0002-9610(01)00709-7]

26 **Langan RC**, Graham JA, Chin AB, Rubinstein AJ, Oza K, Nusbaum JA, Smirniotopoulos J, Kayser R, Jha R, Haddad N, Al-Kawas F, Carroll J, Hanna J, Parker A, Al-Refaie WB, Johnson LB. Laparoscopic-assisted versus open pancreaticoduodenectomy: early favorable physical quality-of-life measures. *Surgery* 2014; **156**: 379-384 [PMID: 24680859 DOI: 10.1016/j.surg.2014.03.018]

27 **Qin T**, Zhang H, Pan S, Liu J, Li D, Chen R, Huang X, Liu Y, Liu J, Cheng W, Chen X, Zhao W, Li J, Tan Z, Huang H, Li D, Zhu F, Yu G, Zhou B, Zheng S, Tang Y, Ke J, Liu X, Chen B, Chen W, Ma H, Xu J, Liu Y, Lin R, Dong Y, Yu Y, Wang M, Qin R; Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Effect of Laparoscopic and Open Pancreatoduodenectomy for Pancreatic or Periampullary Tumors: Three-year Follow-up of a Randomized Clinical Trial. *Ann Surg* 2023 [PMID: 37965767 DOI: 10.1097/SLA.0000000000006149]

28 **Zheng Z**, Xiang G, Tan C, Zhang H, Liu B, Gong J, Mai G, Liu X. Pancreaticoduodenectomy versus duodenum-preserving pancreatic head resection for the treatment of chronic pancreatitis. *Pancreas* 2012; **41**: 147-152 [PMID: 21775913 DOI: 10.1097/MPA.0b013e318221c91b]

29 **Keck T**, Adam U, Makowiec F, Riediger H, Wellner U, Tittelbach-Helmrich D, Hopt UT. Short- and long-term results of duodenum preservation versus resection for the management of chronic pancreatitis: a prospective, randomized study. *Surgery* 2012; **152**: S95-S102 [PMID: 22906892 DOI: 10.1016/j.surg.2012.05.016]

30 **Fischer TD**, Gutman DS, Warner EA, Trevino JG, Hughes SJ, Behrns KE. Local pancreatic head resection: the search for optimal indications through quality of life assessments. *Am J Surg* 2015; **210**: 417-423 [PMID: 26003202 DOI: 10.1016/j.amjsurg.2014.12.049]

31 **Möbius C**, Max D, Uhlmann D, Gumpp K, Behrbohm J, Horvath K, Hauss J, Witzigmann H. Five-year follow-up of a prospective non-randomised study comparing duodenum-preserving pancreatic head resection with classic Whipple procedure in the treatment of chronic pancreatitis. *Langenbecks Arch Surg* 2007; **392**: 359-364 [PMID: 17375317 DOI: 10.1007/s00423-007-0175-4]

32 **Klaiber U**, Alldinger I, Probst P, Bruckner T, Contin P, Köninger J, Hackert T, Büchler MW, Diener MK. Duodenum-preserving pancreatic head resection: 10-year follow-up of a randomized controlled trial comparing the Beger procedure with the Berne modification. *Surgery* 2016; **160**: 127-135 [PMID: 27106794 DOI: 10.1016/j.surg.2016.02.028]

33 **Bachmann K**, Tomkoetter L, Erbes J, Hofmann B, Reeh M, Perez D, Vashist Y, Bockhorn M, Izbicki JR, Mann O. Beger and Frey procedures for treatment of chronic pancreatitis: comparison of outcomes at 16-year follow-up. *J Am Coll Surg* 2014; **219**: 208-216 [PMID: 24880955 DOI: 10.1016/j.jamcollsurg.2014.03.040]

34 **Izbicki JR**, Bloechle C, Knoefel WT, Kuechler T, Binmoeller KF, Broelsch CE. Duodenum-preserving resection of the head of the pancreas in chronic pancreatitis. A prospective, randomized trial. *Ann Surg* 1995; **221**: 350-358 [PMID: 7726670 DOI: 10.1097/00000658-199504000-00004]

35 **Tan CL**, Zhang H, Yang M, Li SJ, Liu XB, Li KZ. Role of original and modified Frey's procedures in chronic pancreatitis. *World J Gastroenterol* 2016; **22**: 10415-10423 [PMID: 28058022 DOI: 10.3748/wjg.v22.i47.10415]

36 **de Rooij T**, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, de Hingh I, Kazemier G, Klaase J, de Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial. *Ann Surg* 2019; **269**: 2-9 [PMID: 30080726 DOI: 10.1097/SLA.0000000000002979]

37 **Kooby DA**, Gillespie T, Bentrem D, Nakeeb A, Schmidt MC, Merchant NB, Parikh AA, Martin RC 2nd, Scoggins CR, Ahmad S, Kim HJ, Park J, Johnston F, Strouch MJ, Menze A, Rymer J, McClaine R, Strasberg SM, Talamonti MS, Staley CA, McMasters KM, Lowy AM, Byrd-Sellers J, Wood WC, Hawkins WG. Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. *Ann Surg* 2008; **248**: 438-446 [PMID: 18791364 DOI: 10.1097/SLA.0b013e318185a990]

38 **van Hilst J**, Strating EA, de Rooij T, Daams F, Festen S, Groot Koerkamp B, Klaase JM, Luyer M, Dijkgraaf MG, Besselink MG; Dutch Pancreatic Cancer Group and LEOPARD trial collaborators. Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial). *Br J Surg* 2019; **106**: 910-921 [PMID: 31012498 DOI: 10.1002/bjs.11147]

39 **Braga M**, Pecorelli N, Ferrari D, Balzano G, Zuliani W, Castoldi R. Results of 100 consecutive laparoscopic distal pancreatectomies: postoperative outcome, cost-benefit analysis, and quality of life assessment. *Surg Endosc* 2015; **29**: 1871-1878 [PMID: 25294551 DOI: 10.1007/s00464-014-3879-x]

40 **Korrel M**, Roelofs A, van Hilst J, Busch OR, Daams F, Festen S, Groot Koerkamp B, Klaase J, Luyer MD, van Oijen MG, Verdonck-de Leeuw IM, Besselink MG; LEOPARD Trial Collaborators. Long-Term Quality of Life after Minimally Invasive vs Open Distal Pancreatectomy in the LEOPARD Randomized Trial. *J Am Coll Surg* 2021; **233**: 730-739.e9 [PMID: 34530127 DOI: 10.1016/j.jamcollsurg.2021.08.687]

41 **Ricci C**, Casadei R, Taffurelli G, Bogoni S, D'Ambra M, Ingaldi C, Pagano N, Pacilio CA, Minni F. Laparoscopic Distal Pancreatectomy in Benign or Premalignant Pancreatic Lesions: Is It Really More Cost-Effective than Open Approach? *J Gastrointest Surg* 2015; **19**: 1415-1424 [PMID: 26001367 DOI: 10.1007/s11605-015-2841-0]

42 **De Pastena M**, Esposito A, Paiella S, Surci N, Montagnini G, Marchegiani G, Malleo G, Secchettin E, Casetti L, Ricci C, Landoni L, Bovo C, Bassi C, Salvia R. Cost-effectiveness and quality of life analysis of laparoscopic and robotic distal pancreatectomy: a propensity score-matched study. *Surg Endosc* 2021; **35**: 1420-1428 [PMID: 32240383 DOI: 10.1007/s00464-020-07528-1]

43 **Kwon W**, Jang JY, Kim JH, Chang YR, Jung W, Kang MJ, Kim SW. An Analysis of Complications, Quality of Life, and Nutritional Index After Laparoscopic Distal Pancreatectomy with Regard to Spleen Preservation. *J Laparoendosc Adv Surg Tech A* 2016; **26**: 335-342 [PMID: 26982249 DOI: 10.1089/lap.2015.0171]

44 **Zhang RC**, Ma J, Mou YP, Yan JF, Zhou YC. Comparison of clinical outcomes and quality of life between laparoscopic distal pancreatectomy with or without spleen preservation. *Surg Endosc* 2021; **35**: 3412-3420 [PMID: 32632480 DOI: 10.1007/s00464-020-07783-2]

45 **Choi SH**, Seo MA, Hwang HK, Kang CM, Lee WJ. Is it worthwhile to preserve adult spleen in laparoscopic distal pancreatectomy? Perioperative and patient-reported outcome analysis. *Surg Endosc* 2012; **26**: 3149-3156 [PMID: 22580876 DOI: 10.1007/s00464-012-2306-4]

46 **Shen Q**, Jiang QF, Tian YW, Yu M, Jia JK, Xue HZ. Appleby operation for carcinoma of the body and tail of the pancreas. *J Cancer Res Ther* 2018; **14**: S1019-S1023 [PMID: 30539839 DOI: 10.4103/0973-1482.199383]

47 **Zhang RC**, Zhang B, Mou YP, Xu XW, Zhou YC, Huang CJ, Zhou JY, Jin WW, Lu C. Comparison of clinical outcomes and quality of life between laparoscopic and open central pancreatectomy with pancreaticojejunostomy. *Surg Endosc* 2017; **31**: 4756-4763 [PMID: 28424909 DOI: 10.1007/s00464-017-5552-7]

48 **Müller MW**, Friess H, Kleeff J, Hinz U, Wente MN, Paramythiotis D, Berberat PO, Ceyhan GO, Büchler MW. Middle segmental pancreatic resection: An option to treat benign pancreatic body lesions. *Ann Surg* 2006; **244**: 909-18; discussion 918-20 [PMID: 17122616 DOI: 10.1097/01.sla.0000247970.43080.23]

49 **Ocuin LM**, Sarmiento JM, Staley CA, Galloway JR, Johnson CD, Wood WC, Kooby DA. Comparison of central and extended left pancreatectomy for lesions of the pancreatic neck. *Ann Surg Oncol* 2008; **15**: 2096-2103 [PMID: 18521682 DOI: 10.1245/s10434-008-9987-x]

50 **Lv A**, Qian HG, Qiu H, Wu JH, Hao CY. Is Central Pancreatectomy Truly Recommendable? A 9-Year Single-Center Experience. *Dig Surg* 2018; **35**: 532-538 [PMID: 29275422 DOI: 10.1159/000485806]

51 **Müller MW**, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Büchler MW. Is there still a role for total pancreatectomy? *Ann Surg* 2007; **246**: 966-74; discussion 974-5 [PMID: 18043098]

52 **Reddy S**, Wolfgang CL, Cameron JL, Eckhauser F, Choti MA, Schulick RD, Edil BH, Pawlik TM. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. *Ann Surg* 2009; **250**: 282-287 [PMID: 19638918 DOI: 10.1097/SLA.0b013e3181ae9f93]

53 **Scholten L**, Latenstein AEJ, van Eijck C, Erdmann J, van der Harst E, Mieog JSD, Molenaar IQ, van Santvoort HC, DeVries JH, Besselink MG; Dutch Pancreatic Cancer Group. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. *Surgery* 2019; **166**: 1017-1026 [PMID: 31500907 DOI: 10.1016/j.surg.2019.07.025]

54 **Pulvirenti A**, Pea A, Rezaee N, Gasparini C, Malleo G, Weiss MJ, Cameron JL, Wolfgang CL, He J, Salvia R. Perioperative outcomes and long-term quality of life after total pancreatectomy. *Br J Surg* 2019; **106**: 1819-1828 [PMID: 31282569 DOI: 10.1002/bjs.11185]

55 **Scholten L**, Stoop TF, Del Chiaro M, Busch OR, van Eijck C, Molenaar IQ, de Vries JH, Besselink MG; Dutch Pancreatic Cancer Group. Systematic review of functional outcome and quality of life after total pancreatectomy. *Br J Surg* 2019; **106**: 1735-1746 [PMID: 31502658 DOI: 10.1002/bjs.11296]

56 **Casadei R**, Ricci C, Taffurelli G, Guariniello A, Di Gioia A, Di Marco M, Pagano N, Serra C, Calculli L, Santini D, Minni F. Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. *J Gastrointest Surg* 2016; **20**: 1595-1607 [PMID: 27418262 DOI: 10.1007/s11605-016-3201-4]

57 **Hartwig W**, Gluth A, Hinz U, Bergmann F, Spronk PE, Hackert T, Werner J, Büchler MW. Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. *Ann Surg* 2015; **261**: 537-546 [PMID: 24979606 DOI: 10.1097/SLA.0000000000000791]

58 **Watanabe Y**, Ohtsuka T, Matsunaga T, Kimura H, Tamura K, Ideno N, Aso T, Miyasaka Y, Ueda J, Takahata S, Igarashi H, Inoguchi T, Ito T, Tanaka M. Long-term outcomes after total pancreatectomy: special reference to survivors' living conditions and quality of life. *World J Surg* 2015; **39**: 1231-1239 [PMID: 25582768 DOI: 10.1007/s00268-015-2948-1]

59 **Clayton HA**, Davies JE, Pollard CA, White SA, Musto PP, Dennison AR. Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the leicester general hospital. *Transplantation* 2003; **76**: 92-98 [PMID: 12865792 DOI: 10.1097/01.TP.0000054618.03927.70]

60 **Chinnakotla S**, Radosevich DM, Dunn TB, Bellin MD, Freeman ML, Schwarzenberg SJ, Balamurugan AN, Wilhelm J, Bland B, Vickers SM, Beilman GJ, Sutherland DE, Pruett TL. Long-term outcomes of total pancreatectomy and islet auto transplantation for hereditary/genetic pancreatitis. *J Am Coll Surg* 2014; **218**: 530-543 [PMID: 24655839 DOI: 10.1016/j.jamcollsurg.2013.12.037]

61 **Wilson GC**, Sutton JM, Abbott DE, Smith MT, Lowy AM, Matthews JB, Rilo HL, Schmulewitz N, Salehi M, Choe K, Brunner J, Hanseman DJ, Sussman JJ, Edwards MJ, Ahmad SA. Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? *Ann Surg* 2014; **260**: 659-65; discussion 665-7 [PMID: 25203883 DOI: 10.1097/SLA.0000000000000920]

62 **Walsh RM**, Saavedra JR, Lentz G, Guerron AD, Scheman J, Stevens T, Trucco M, Bottino R, Hatipoglu B. Improved quality of life following total pancreatectomy and auto-islet transplantation for chronic pancreatitis. *J Gastrointest Surg* 2012; **16**: 1469-1477 [PMID: 22673773 DOI: 10.1007/s11605-012-1914-6]

63 **Morgan K**, Owczarski SM, Borckardt J, Madan A, Nishimura M, Adams DB. Pain control and quality of life after pancreatectomy with islet autotransplantation for chronic pancreatitis. *J Gastrointest Surg* 2012; **16**: 129-33; discussion 133-4 [PMID: 22042566 DOI: 10.1007/s11605-011-1744-y]

64 **Stoop TF**, Ateeb Z, Ghorbani P, Scholten L, Arnelo U, Besselink MG, Del Chiaro M. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. *Ann Surg Oncol* 2020; **27**: 587-596 [PMID: 31562603 DOI: 10.1245/s10434-019-07853-3]

65 **Wu W**, Dodson R, Makary MA, Weiss MJ, Hirose K, Cameron JL, Ahuja N, Pawlik TM, Wolfgang CL, He J. A Contemporary Evaluation of the Cause of Death and Long-Term Quality of Life After Total Pancreatectomy. *World J Surg* 2016; **40**: 2513-2518 [PMID: 27177647 DOI: 10.1007/s00268-016-3552-8]

66 **Barbier L**, Jamal W, Dokmak S, Aussilhou B, Corcos O, Ruszniewski P, Belghiti J, Sauvanet A. Impact of total pancreatectomy: short- and long-term assessment. *HPB (Oxford)* 2013; **15**: 882-892 [PMID: 23458647 DOI: 10.1111/hpb.12054]

67 **Bellin MD**, Schwarzenberg SJ, Cook M, Sutherland DE, Chinnakotla S. Pediatric Autologous Islet Transplantation. *Curr Diab Rep* 2015; **15**: 67 [PMID: 26275441 DOI: 10.1007/s11892-015-0639-9]

68 **Sutherland DE**, Radosevich DM, Bellin MD, Hering BJ, Beilman GJ, Dunn TB, Chinnakotla S, Vickers SM, Bland B, Balamurugan AN, Freeman ML, Pruett TL. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. *J Am Coll Surg* 2012; **214**: 409-24; discussion 424-6 [PMID: 22397977 DOI: 10.1016/j.jamcollsurg.2011.12.040]

69 **Bellin MD**, Freeman ML, Schwarzenberg SJ, Dunn TB, Beilman GJ, Vickers SM, Chinnakotla S, Balamurugan AN, Hering BJ, Radosevich DM, Moran A, Sutherland DE. Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; **9**: 793-799 [PMID: 21683160 DOI: 10.1016/j.cgh.2011.04.024]

70 **Chinnakotla S**, Bellin MD, Schwarzenberg SJ, Radosevich DM, Cook M, Dunn TB, Beilman GJ, Freeman ML, Balamurugan AN, Wilhelm J, Bland B, Jimenez-Vega JM, Hering BJ, Vickers SM, Pruett TL, Sutherland DE. Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indication, surgical techniques, postoperative management, and long-term outcomes. *Ann Surg* 2014; **260**: 56-64 [PMID: 24509206 DOI: 10.1097/SLA.0000000000000569]

71 **Solomina J**, Gołębiewska J, Kijek MR, Kotukhov A, Bachul PJ, Basto L, Gołąb K, Konsur E, Cieply K, Fillman N, Wang LJ, Thomas CC, Philipson LH, Tibudan M, Dębska-Ślizień A, Fung J, Gelrud A, Matthews JB, Witkowski P. Pain Control, Glucose Control, and Quality of Life in Patients With Chronic Pancreatitis After Total Pancreatectomy With Islet Autotransplantation: A Preliminary Report. *Transplant Proc* 2017; **49**: 2333-2339 [PMID: 29198673 DOI: 10.1016/j.transproceed.2017.10.010]

72 **Kausch W**. Das Carcinom der Papilla duodeni und seine radikale Entfernung. *Beitr Klin Chir* 1912; **78**: 439–486 [DOI: 10.1515/9783110864731-008]

73 **Whipple AO**, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. *Ann Surg* 1935; **102**: 763-779 [PMID: 17856666 DOI: 10.1097/00000658-193510000-00023]

74 **Balcom JH 4th**, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. *Arch Surg* 2001; **136**: 391-398 [PMID: 11296108 DOI: 10.1001/archsurg.136.4.391]

75 **Watson K**. Carcinoma of ampulla of vater successful radical resection. *Br J Surg* 1944; **31**: 368-373 [DOI: 10.1002/bjs.18003112406]

76 **Traverso LW**, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. *Surg Gynecol Obstet* 1978; **146**: 959-962 [PMID: 653575]

77 **Park HH**, Kim HY, Jung SE, Lee SC, Park KW. Long-term functional outcomes of PPPD in children--Nutritional status, pancreatic function, GI function and QOL. *J Pediatr Surg* 2016; **51**: 398-402 [PMID: 26382285 DOI: 10.1016/j.jpedsurg.2015.08.010]

78 **Gagner M**, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. *Surg Endosc* 1994; **8**: 408-410 [PMID: 7915434 DOI: 10.1007/BF00642443]

79 Beger HG, Krautzberger W, Bittner R, Büchler M, Limmer J. Duodenum-preserving resection of the head of the pancreas in patients with severe chronic pancreatitis. *Surgery* 1985; **97**: 467-473 [PMID: 3983823]

80 **Diener MK**, Hüttner FJ, Kieser M, Knebel P, Dörr-Harim C, Distler M, Grützmann R, Wittel UA, Schirren R, Hau HM, Kleespies A, Heidecke CD, Tomazic A, Halloran CM, Wilhelm TJ, Bahra M, Beckurts T, Börner T, Glanemann M, Steger U, Treitschke F, Staib L, Thelen K, Bruckner T, Mihaljevic AL, Werner J, Ulrich A, Hackert T, Büchler MW; ChroPac Trial Group. Partial pancreatoduodenectomy versus duodenum-preserving pancreatic head resection in chronic pancreatitis: the multicentre, randomised, controlled, double-blind ChroPac trial. *Lancet* 2017; **390**: 1027-1037 [PMID: 28901935 DOI: 10.1016/S0140-6736(17)31960-8]

81 **Pothula Rajendra VK**, Sivanpillay Mahadevan S, Parvathareddy SR, Nara BK, Gorlagunta Ramachandra M, Tripuraneni Venkata AC, Bathalapalli JM, Gudi VP, Sampath T. Frey's pancreaticojejunostomy in tropical pancreatitis: assessment of quality of life. A prospective study. *World J Surg* 2014; **38**: 3235-3247 [PMID: 25189439 DOI: 10.1007/s00268-014-2732-7]

82 **Aimoto T**, Uchida E, Matsushita A, Kawano Y, Mizutani S, Kobayashi T. Long-term outcomes after Frey's procedure for chronic pancreatitis with an inflammatory mass of the pancreatic head, with special reference to locoregional complications. *J Nippon Med Sch* 2013; **80**: 148-154 [PMID: 23657068 DOI: 10.1272/jnms.80.148]

83 **Nimura Y**. Experience of Appleby's operation for advanced carcinoma of the pancreatic body and tail. *Shujutsu* 1976; **30**: 885-889

84 **Guillemin P**, Bessot M. [Chronic calcifying pancreatitis in renal tuberculosis: pancreatojejunostomy using an original technic]. *Mem Acad Chir (Paris)* 1957; **83**: 869-871 [PMID: 13503655]

85 **Letton AH**, Wilson JP. Traumatic severance of pancreas treated by Roux-Y anastomosis. *Surg Gynecol Obstet* 1959; **109**: 473-478 [PMID: 14416087]

86 **Rockey EW**. Total pancreatectomy for carcinoma: Case report. *Ann Surg* 1943; **118**: 603-611 [PMID: 17858293 DOI: 10.1097/00000658-194310000-00008]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 1, 2023

**First decision:** December 18, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gul S, India **S-Editor:** Fan JR **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 PRISMA flow diagram.** QOL: Quality of life; PD: Pancreaticoduodenectomy; DPPHR: Duodenum-preserving pancreatic head resection; DP: Distal pancreatectomy; CP: Central pancreatectomy; TP: Total pancreatectomy.

**Table 1 Articles retrieved from literature reporting quality of life after pancreaticoduodenectomy**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study design** | **Relevant patients** | **Total patients** | **Moments of assessment** | **Operation type** | **Questionnaires** |
| Chan *et al*[12] | 2012 | Mexico | Prospective single-center study | 37 | 37 | PRE, 1, 3, 6 and 12 months | PD | SF-36 |
| Gerstenhaber *et al*[11] | 2013 | Israel | Retrospective, single-center study | 70 | 168 | At discharge, 3, 6 and 12 months | PD | EORTC QLQ-C30 |
| Rees *et al*[14] | 2013 | United Kingdom | Prospective single-center study | 41 | 53 | PRE, 6 wk, 3, 6, 12, 18 and 24 months | PD | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Park *et al*[77] | 2016 | Korea | Retrospective, single-center study | 10 | 15 | 10.5 (3, 18) yr | PPPD | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Fong *et al*[9] | 2017 | United States | Retrospective, single-center study | 245 | 305 | 9.1 (5.1, 21.2) yr postoperatively | PD | EQ-5D-5L; EORTC QLQ-C30 |
| Laitinen *et al*[8] | 2017 | Finland | Prospective single-center study | 47 | 47 | PRE, 3, 6, 12, 18 and 24 months | PD | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Heerkens *et al*[15] | 2018 | Netherlands | Prospective single-center study | 118 | 137 | 1, 3, 6 and 12 months | PD | RAND-36; EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Diener *et al*[80] | 2017 | Germany | Multicenter, randomized controlled trial | 226 | 250 | 24 months | PD and DPPHR | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Allen *et al*[13] | 2018 | United States | Retrospective, global study | 927 | 7605 | 2.0 (0.7, 4.3) yr | PD | SF-36; GSRS |
| Klaiber *et al*[24] | 2020 | Germany | Prospective, randomized controlled trial | 96 | 188 | PRE, 1 months, 34.3 (16, 57) months | PD and PPPD | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Balduzzi *et al*[16] | 2020 | Italy | Retrospective, single-center study | 47 | 75 | 60 (12, 240) months | PD | Pancreatitis Quality of Life Instrument; DSMQ |
| Jung *et al*[18] | 2022 | South Korea | Retrospective, single-center study | 122 | 122 | 12 months | PD | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Qin *et al*[27] | 2023 | China | Prospective, randomized controlled trial | 656 | 200 | 3 yr | PD | EQ-5D-3L |

EORTC: European Organization for Research and Treatment of Cancer; PRE: Preoperative quality of life; PD: Pancreaticoduodenectomy; PPPD: Pylorus-preserving pancreaticoduodenectomy; DPPHR: Duodenum-preserving pancreatic head resection; SF-36: 36-item Short; EQ-5D: European Quality of Life 5-dimension.

**Table 2 Articles retrieved from literature reporting quality of life after duodenum-preserving pancreatic head resection**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study design** | **Relevant patients** | **Total patients** | **Moments of assessment** | **Operation type** | **Questionnaires** |
| Bachmann *et al*[33] | 2014 | Germany | Randomized controlled trail | 74 | 74 | 16 (14, 18) yr | DPPHR | EORTC QLQ-C30 |
| Tan *et al*[35] | 2016 | China | Retrospective, single-center study | 80 | 156 | 50 months | The Frey and modified Frey | EORTC QLQ-C30 |
| Pothula *et al*[81] | 2014 | India | Prospective single-center study | 25 | 25 | PRE, 12 months | The Frey | SF-36 |
| Klaiber *et al*[32] | 2016 | Germany | Prospective single-center study | 40 | 65 | 129 (111, 137) months | The Beger and modified Beger | EORTC QLQ-C30;  EORTC QLQ-PAN26 |
| Keck *et al*[29] | 2012 | Germany | Prospective, randomized controlled trial | 85 | 85 | > 5 yr | The Frey and Beger | EORTC QLQ-C30 |
| Fischer *et al*[30] | 2015 | United States | Retrospective, single-center study | 17 | 45 | 40.7 (23.7, 53.7) months | DPPHR | EORTC QLQ-C30 |
| Aimoto *et al*[82] | 2013 | Japan | Retrospective, single-center study | 16 | 16 | 70.8 months for the Frey, 119.8 months for PPPD | The Frey and PPPD | EORTC QLQ-C30 |

EORTC: European Organization for Research and Treatment of Cancer; DPPHR: Duodenum-preserving pancreatic head resection; PPPD: Pylorus-preserving pancreaticoduodenectomy; PRE: Preoperative quality of life; SF-36: 36-item Short.

**Table 3 Articles retrieved from literature reporting quality of life after distal pancreatectomy and central pancreatectomy**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study design** | **Relevant patients** | **Total patients** | **Moments of assessment** | **Operation type** | **Questionnaires** |
| van Hilst *et al*[38] | 2019 | Netherlands | Prospective, randomized controlled trial | 63 | 108 | 1 yr | ODP and LDP | EQ-5D; EORTC QLQ-C30; EORTC QLQ-PAN26 |
| De Rooij *et al*[36] | 2019 | Netherlands | Multicenter, randomized controlled trial | 108 | 111 | From postoperative day 3 to 30 | ODP and MIDP | EQ-5D-3L; EORTC QLQ-C30 |
| Korrel *et al*[40] | 2021 | Netherlands | Multicenter, randomized controlled trial | 62 | 84 | 44 (39, 50) months | ODP and MIDP | EQ-5D; EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Zhang *et al*[44] | 2021 | China | Retrospective, single-center study | 102 | 110 | 106 (62, 189) months | LSPDP and LDPS | SF-36 |
| Ricci *et al*[41] | 2015 | Italy | Retrospective, single-center study | 54 | 81 | 12 months | ODP and LDP | EORTC QLQ-C30 |
| De Pastena *et al*[42] | 2021 | Italy | Multicenter, randomized controlled trial | 79 | 152 | 52 months | LDP and RDP | EQ-5D; EORTC QLQ-C30 |
| Choi *et al*[45] | 2012 | Korea | Retrospective, single-center study | 61 | 72 | 23 (3, 76) months | LSPDP and LDPS | - |
| Braga *et al*[39] | 2015 | Italy | Retrospective, single-center study | 100 | 170 | 1 and 3 months | LDP | SF-8 |
| Kwon *et al*[43] | 2016 | Korea | Retrospective analysis of prospective gathered data, single-center | 104 | 111 | PRE, at discharge, 3, 6 and 12 months | LSPDP and LDPS | EORTC QLQ-C30 |
| Zhang *et al*[47] | 2017 | China | Retrospective, single-center study | 36 | 36 | 45 (4, 216) months | LCP and OCP | SF-36 |
| Lv *et al*[50] | 2018 | China | Retrospective, single-center study | 42 | 42 | 53 (21, 117) months | CP and DP | EORTC QLQ-C30 |

EORTC: European Organization for Research and Treatment of Cancer; ODP: Open distal pancreatectomy; LDP: Laparoscopic distal pancreatectomy; MIDP: Minimally invasive distal pancreatectomy; LSPDP: Laparoscopic spleen-preserving distal pancreatectomy; LDPS: Laparoscopic distal pancreatectomy with splenectomy; RDP: Robotic distal pancreatectomy; LCP: Laparoscopic central pancreatectomy; OCP: Open central pancreatectomy; PRE: Preoperative quality of life; SF-36: 36-item Short; EQ-5D: European Quality of Life 5-dimension.

**Table 4 Articles retrieved from literature reporting quality of life after total pancreatectomy**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Study design** | **Relevant patients** | **Total patients** | **Moments of assessment** | **Operation type** | **Questionnaires** |
| Wilson *et al*[61] | 2014 | United States | Retrospective, single-center study | 112 | 166 | At least 5 yr (60 to 132 months) | TPIAT | SF-36 |
| Pulvirenti *et al*[54] | 2019 | Italy and United States | Retrospective, multicenter study | 94 | 329 | 63 (20, 109) months | TP | SF-36; EORTC QLQ-PAN26 |
| Hartwig *et al*[57] | 2015 | Germany | Retrospective, single-center study | 81 | 434 | 24, 48, 72, 96 and 120 months | TP | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Chinnakotla *et al*[70] | 2014 | United States | Retrospective, single-center study | 30 | 75 | PRE, 3, 6, 12 months and annually post-operative | TPIAT for children | Rand-36 |
| Stoop *et al*[64] | 2020 | Netherlands | Retrospective, single-center study | 53 | 145 | 21 (13, 54) months | TP | EORTC QLQ-C30; EORTC QLQ-PAN26; Problem Areas in Diabetes; Diabetes Treatment Satisfaction Questionnaire |
| Chinnakotla *et al*[60] | 2014 | United States | Retrospective analysis of prospective gathered data, single-center | 80 | 484 | 3, 6, 12 and 24 months | TPIAT | RAND-36 |
| Bellin *et al*[67] | 2015 | United States | Retrospective, single-center study | > 100 | > 100 | 12, 24 and 36 months | TPIAT for children | SF-36 |
| Wu *et al*[65] | 2016 | China | Retrospective, single-center study | 36 | 186 | 5.9 yr | TP | SF-36; Audit of Diabetes Dependent QoL; EORTC QLQ-PAN26 |
| Watanabe *et al*[58] | 2015 | Japan | Retrospective, single-center study | 25 | 44 | 21 (2, 222) months | TP | SF-36 |
| Walsh *et al*[62] | 2012 | United States | Prospective single-center study | 20 | 20 | 12 (6.75, 24) months | TPIAT | Visual Analogue Pain Scale; 20 Point Depression Anxiety Stress Scale; 10-point Pain Disability Index |
| Scholten *et al*[53] | 2019 | Netherlands | Retrospective, multicenter study | 60 | 148 | 3 and 5 yr | TP | EQ-5D; EORTC QLQ-C30 |
| Casadei *et al*[56] | 2016 | Italy | Prospective single-center study | 119 | 257 | TP 28 (18, 36) months, PD 27 (14, 27) months | TP and PD | EQ-5D-5L |
| Barbier *et al*[66] | 2013 | United States | Retrospective, single-center study | 25 | 56 | 35 (4, 168) months | TP | EORTC QLQ-C30; EORTC QLQ-PAN26 |
| Solomina *et al*[71] | 2017 | United States | Retrospective analysis of prospective gathered data, single-center | 20 | 20 | 28 (2, 38) months | TPIAT | SF-36 |

TPIAT: Total pancreatectomy and islet cell auto-transplantation; PRE: Preoperative quality of life; EORTC: European Organization for Research and Treatment of Cancer; SF-36: 36-item Short; EQ-5D: European Quality of Life 5-dimension; TP: Total pancreatectomy.